Neurizon Therapeutics Limited
ABN 35 094 006 023
www.neurizon.com

20 February 2026

ASX Market Announcements
ASX Limited
Level 4
Stock Exchange Centre
20 Bridge Street
SYDNEY NSW 2000

Dear Sir/Madam

RESULTS OF GENERAL MEETING

In accordance with Listing Rule 3.13.2 and Section 251AA of the *Corporations Act 2001* (Cth), we advise details of the resolutions and the proxies received in respect of each resolution as set out in the attached proxy summary.

Yours sincerely,
NEURIZON THERAPEUTICS LIMITED



Stefan Ross
Company Secretary

This announcement has been authorized for release by the Board of Neurizon Therapeutics Limited.

For further information, please contact:

Neurizon Therapeutics
Lidija Damjanovic
Marketing & Corporate Affairs
Email: lidija@neurizon.com
Phone: +61 (0) 425 700 504

Australia Investor Relations
Henry Jordan
Six Degrees Investor Relations
Email: henry.jordan@sdir.com.au
Phone: +61 (0) 431 271 538

U.S. Investor Relations
Matthew Selinger
Integrous Communications
Email: mselinger@integcom.us
Phone: +1 415-572-8152

About Neurizon Therapeutics Limited

Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease. Neurizon's strategy is to accelerate access to effective ALS treatments for patients while exploring the potential of NUZ-001 for broader neurodegenerative applications. Through international collaborations and rigorous clinical programs, Neurizon is dedicated to creating new horizons for patients and families impacted by complex neural disorders. NUZ-001 is an investigational product and is not approved for commercial use in any jurisdiction.

Neurizon Investor Hub

We encourage you to utilise our Investor Hub for any enquiries regarding this announcement or other aspects concerning Neurizon.
This platform offers an opportunity to submit questions, share comments, and view video summaries of key announcements.

To access Neurizon Investor Hub please scan the QR code or visit
https://investorhub.neurizon.com

Neurizon® is a registered trademark of Neurizon Therapeutics Limited.

Neurizon Therapeutics Limited
ABN 35 094 006 023
www.neurizon.com

Neurizon Therapeutics Limited
General Meeting
Friday, 20 February 2026
Voting Results

The following information is provided in accordance with section 251AA(2) of *Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2*:

Resolution Details				Show of Hands (S) or Poll (P)	Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Res. Results
Resolution		Resolution Type	If s250U applies	S or P	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried /Not Carried
1.	Ratification of prior issue of 79,330,864 Shares	Ordinary	N/A	P	66,347,470 88.52%	714,986 0.95%	7,888,895 10.53%	4,007 -	74,531,681 99.05%	714,986 0.95%	4,007 -	Carried
2.	Approval to issue shares to Mr Sergio Duchini (and/or his nominee(s) or associates) in relation to the Placement	Ordinary	N/A	P	107,146,295 91.92%	1,550,473 1.33%	7,867,068 6.75%	1,781,485 -	115,308,679 98.67%	1,550,473 1.33%	1,781,485 -	Carried
3.	Approval to issue shares to Mr Marcus Hughes (and/or his nominee(s) or associates) in relation to the Placement	Ordinary	N/A	P	91,525,759 90.67%	1,550,473 1.54%	7,867,068 7.79%	1,781,485 -	99,688,143 98.47%	1,550,473 1.53%	1,781,485 -	Carried
4.	Approval to issue shares to Dr Michael Thurn (and/or his nominee(s) or associates) in relation to the Placement	Ordinary	N/A	P	107,146,295 91.92%	1,550,473 1.33%	7,867,068 6.75%	1,781,485 -	115,308,679 98.67%	1,550,473 1.33%	1,781,485 -	Carried

Resolution Details				Show of Hands (S) or Poll (P)	Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Res. Results
Resolution		Resolution Type	If s250U applies	S or P	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried /Not Carried
5.	Approval to issue shares to Dr Katie MacFarlane (and/or her nominee(s) or associates) in relation to the Placement	Ordinary	N/A	P	107,062,961 91.91%	1,550,473 1.33%	7,867,068 6.75%	1,864,819 -	114,962,187 98.67%	1,550,473 1.33%	2,127,977 -	Carried
6.	Approval to issue Convertible Notes to Obsidian Global GP, LLC (and/or its nominee(s))	Ordinary	N/A	P	109,648,161 92.69%	748,986 0.63%	7,899,145 6.68%	49,029 -	117,842,622 99.37%	748,986 0.63%	49,029 -	Carried
7.	Approval to issue placement shares to Obsidian Global GP, LLC (and/or its nominee(s))	Ordinary	N/A	P	109,624,661 92.67%	772,486 0.65%	7,899,145 6.68%	49,029 -	117,819,122 99.35%	772,486 0.65%	49,029 -	Carried

* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.